AU2014360758B2 - Methods of treating and preventing alloantibody driven chronic graft versus host disease - Google Patents
Methods of treating and preventing alloantibody driven chronic graft versus host disease Download PDFInfo
- Publication number
- AU2014360758B2 AU2014360758B2 AU2014360758A AU2014360758A AU2014360758B2 AU 2014360758 B2 AU2014360758 B2 AU 2014360758B2 AU 2014360758 A AU2014360758 A AU 2014360758A AU 2014360758 A AU2014360758 A AU 2014360758A AU 2014360758 B2 AU2014360758 B2 AU 2014360758B2
- Authority
- AU
- Australia
- Prior art keywords
- cgvhd
- substituted
- inhibitor
- unsubstituted
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NAQYQSPFDLXJIK-UHFFFAOYSA-N C#CC(N(CCC1)CC1[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O Chemical compound C#CC(N(CCC1)CC1[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O NAQYQSPFDLXJIK-UHFFFAOYSA-N 0.000 description 1
- KOMVUMRPJMRZLN-FARCUNLSSA-N C/C=C/C(N(CCC1)CC1[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O Chemical compound C/C=C/C(N(CCC1)CC1[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O KOMVUMRPJMRZLN-FARCUNLSSA-N 0.000 description 1
- BHQPOACREKDSLZ-QHHAFSJGSA-N C/C=C/C(NCC[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O Chemical compound C/C=C/C(NCC[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O BHQPOACREKDSLZ-QHHAFSJGSA-N 0.000 description 1
- IVGPJIMEFZQIBY-XVNBXDOJSA-N C/C=C/C1OC1N(C)CC[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1 Chemical compound C/C=C/C1OC1N(C)CC[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1 IVGPJIMEFZQIBY-XVNBXDOJSA-N 0.000 description 1
- KALPRSFUZYGTNU-UHFFFAOYSA-N C=CC(N(CC1)CCC1[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O Chemical compound C=CC(N(CC1)CCC1[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O KALPRSFUZYGTNU-UHFFFAOYSA-N 0.000 description 1
- XYFPWWZEPKGCCK-UHFFFAOYSA-N C=CC(N(CCC1)CC1[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O Chemical compound C=CC(N(CCC1)CC1[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O XYFPWWZEPKGCCK-UHFFFAOYSA-N 0.000 description 1
- BZDZSNZQRWOSGZ-UHFFFAOYSA-N C=CS(N(CCC1)CC1[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)(=O)=O Chemical compound C=CS(N(CCC1)CC1[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)(=O)=O BZDZSNZQRWOSGZ-UHFFFAOYSA-N 0.000 description 1
- YEYDWIOPZIMKTI-UHFFFAOYSA-N C=CS(NCC[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)(=O)=O Chemical compound C=CS(NCC[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)(=O)=O YEYDWIOPZIMKTI-UHFFFAOYSA-N 0.000 description 1
- AJSZEZDUYDTBIB-RMKNXTFCSA-N CN(CC[n](c1c2c(N)ncn1)nc2-c(cc1)ccc1Oc1ccccc1)C1OC1/C=C/COC Chemical compound CN(CC[n](c1c2c(N)ncn1)nc2-c(cc1)ccc1Oc1ccccc1)C1OC1/C=C/COC AJSZEZDUYDTBIB-RMKNXTFCSA-N 0.000 description 1
- MVUKBEZYHBERNA-UHFFFAOYSA-N CNS(C=C)(=O)=O Chemical compound CNS(C=C)(=O)=O MVUKBEZYHBERNA-UHFFFAOYSA-N 0.000 description 1
- OGWAZVFLLSPIGM-VMPITWQZSA-N COC/C=C/C(NCC[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O Chemical compound COC/C=C/C(NCC[n](c1ncnc(N)c11)nc1-c(cc1)ccc1Oc1ccccc1)=O OGWAZVFLLSPIGM-VMPITWQZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020204276A AU2020204276A1 (en) | 2013-12-02 | 2020-06-26 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| AU2022203810A AU2022203810B2 (en) | 2013-12-02 | 2022-06-02 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| AU2024278490A AU2024278490A1 (en) | 2013-12-02 | 2024-12-17 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361910944P | 2013-12-02 | 2013-12-02 | |
| US61/910,944 | 2013-12-02 | ||
| US201461973178P | 2014-03-31 | 2014-03-31 | |
| US61/973,178 | 2014-03-31 | ||
| PCT/US2014/068177 WO2015084857A1 (en) | 2013-12-02 | 2014-12-02 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020204276A Division AU2020204276A1 (en) | 2013-12-02 | 2020-06-26 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014360758A1 AU2014360758A1 (en) | 2016-06-16 |
| AU2014360758B2 true AU2014360758B2 (en) | 2020-03-26 |
Family
ID=53270044
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014360758A Active AU2014360758B2 (en) | 2013-12-02 | 2014-12-02 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| AU2020204276A Abandoned AU2020204276A1 (en) | 2013-12-02 | 2020-06-26 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| AU2022203810A Expired - Fee Related AU2022203810B2 (en) | 2013-12-02 | 2022-06-02 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| AU2024278490A Pending AU2024278490A1 (en) | 2013-12-02 | 2024-12-17 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020204276A Abandoned AU2020204276A1 (en) | 2013-12-02 | 2020-06-26 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| AU2022203810A Expired - Fee Related AU2022203810B2 (en) | 2013-12-02 | 2022-06-02 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| AU2024278490A Pending AU2024278490A1 (en) | 2013-12-02 | 2024-12-17 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20150157634A1 (enExample) |
| EP (1) | EP3076975A4 (enExample) |
| JP (5) | JP2017501140A (enExample) |
| KR (2) | KR20230104754A9 (enExample) |
| CN (2) | CN105939717B (enExample) |
| AU (4) | AU2014360758B2 (enExample) |
| BR (1) | BR112016012158A2 (enExample) |
| CA (2) | CA3210338A1 (enExample) |
| EA (1) | EA201691020A1 (enExample) |
| IL (4) | IL315228A (enExample) |
| MX (2) | MX389020B (enExample) |
| PH (2) | PH12020552048A1 (enExample) |
| TW (3) | TW202228700A (enExample) |
| WO (1) | WO2015084857A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| CA3103411A1 (en) | 2013-10-25 | 2015-04-30 | Pharmacyclics Llc | Use of ibrutinib for treating and preventing chronic graft versus host disease |
| AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
| EP3868374A3 (en) | 2016-03-22 | 2021-11-10 | Mayo Foundation for Medical Education and Research | Using fatty acid synthase inhibitors to treat fibrosis |
| WO2018002958A1 (en) * | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
| US20200054721A1 (en) * | 2016-10-21 | 2020-02-20 | Bruce R. Blazar | Materials and methods for treating or preventing graft-versus-host-disease |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
| US12496303B2 (en) | 2020-10-19 | 2025-12-16 | Washington University | Conditioning agents for use in allogeneic hematopoietic stem cell transplantation |
| US20240025990A1 (en) * | 2020-12-01 | 2024-01-25 | City Of Hope | Prevention and treatment of graft-versus-host disease (gvhd) |
| CN116782946A (zh) * | 2021-01-30 | 2023-09-19 | 百济神州有限公司 | 使用btk抑制剂治疗慢性活动性抗体介导的排斥的方法 |
| US12624539B2 (en) | 2023-02-28 | 2026-05-12 | Toto Ltd. | Wall-mounted flush toilet |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8476284B2 (en) * | 2006-09-22 | 2013-07-02 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| WO2015061751A1 (en) * | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Methods of treating and preventing graft versus host disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| US20060182723A1 (en) * | 2005-01-25 | 2006-08-17 | Spellberg Brad J | Methods for treating refractory infections in neutropenic individuals |
| KR20080098490A (ko) * | 2006-01-13 | 2008-11-10 | 파마시클릭스, 인코포레이티드 | 티로신 키나제 억제제 및 이의 용도 |
| CN102159214A (zh) * | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| US8765754B2 (en) * | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| EP2473523A2 (en) * | 2009-08-31 | 2012-07-11 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| MX380504B (es) * | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| US20120071497A1 (en) * | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| ES2548414T3 (es) * | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
| HK1206624A1 (en) * | 2012-04-11 | 2016-01-15 | Acerta Pharma B.V. | Bruton's tyrosine kinase inhibitors for hematopoietic mobilization |
| US10722577B2 (en) * | 2012-05-25 | 2020-07-28 | Sloan Kettering Institute For Cancer Research | Methods for treating GI syndrome and graft versus host disease |
| CN104994875B (zh) * | 2013-02-15 | 2018-10-09 | 免疫医疗公司 | 嵌合和人源化抗组蛋白抗体 |
| IL315294A (en) * | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
-
2014
- 2014-12-02 TW TW110135203A patent/TW202228700A/zh unknown
- 2014-12-02 IL IL315228A patent/IL315228A/en unknown
- 2014-12-02 CA CA3210338A patent/CA3210338A1/en active Pending
- 2014-12-02 JP JP2016536248A patent/JP2017501140A/ja not_active Ceased
- 2014-12-02 US US14/558,297 patent/US20150157634A1/en not_active Abandoned
- 2014-12-02 TW TW112113060A patent/TW202402295A/zh unknown
- 2014-12-02 PH PH1/2020/552048A patent/PH12020552048A1/en unknown
- 2014-12-02 EP EP14867905.3A patent/EP3076975A4/en not_active Withdrawn
- 2014-12-02 WO PCT/US2014/068177 patent/WO2015084857A1/en not_active Ceased
- 2014-12-02 MX MX2016006955A patent/MX389020B/es unknown
- 2014-12-02 KR KR1020237021643A patent/KR20230104754A9/ko active Pending
- 2014-12-02 AU AU2014360758A patent/AU2014360758B2/en active Active
- 2014-12-02 BR BR112016012158A patent/BR112016012158A2/pt not_active Application Discontinuation
- 2014-12-02 KR KR1020167015178A patent/KR20160085817A/ko not_active Abandoned
- 2014-12-02 TW TW103141826A patent/TWI743019B/zh not_active IP Right Cessation
- 2014-12-02 CN CN201480074674.4A patent/CN105939717B/zh active Active
- 2014-12-02 CN CN201910760757.3A patent/CN110478353B/zh active Active
- 2014-12-02 CA CA2932255A patent/CA2932255C/en active Active
- 2014-12-02 EA EA201691020A patent/EA201691020A1/ru unknown
- 2014-12-02 IL IL292522A patent/IL292522A/en unknown
-
2016
- 2016-05-18 IL IL245715A patent/IL245715A0/en unknown
- 2016-05-27 MX MX2022000209A patent/MX2022000209A/es unknown
- 2016-06-02 PH PH12016501051A patent/PH12016501051A1/en unknown
-
2017
- 2017-12-01 US US15/829,087 patent/US20180078558A1/en not_active Abandoned
-
2020
- 2020-02-18 JP JP2020025682A patent/JP2020105181A/ja not_active Ceased
- 2020-06-26 AU AU2020204276A patent/AU2020204276A1/en not_active Abandoned
- 2020-07-29 US US16/942,151 patent/US20210177854A1/en not_active Abandoned
- 2020-08-12 IL IL276683A patent/IL276683A/en unknown
-
2022
- 2022-04-29 US US17/733,419 patent/US20230100137A1/en not_active Abandoned
- 2022-06-02 AU AU2022203810A patent/AU2022203810B2/en not_active Expired - Fee Related
- 2022-11-25 JP JP2022188655A patent/JP2023029899A/ja not_active Ceased
-
2023
- 2023-09-25 US US18/372,495 patent/US20240293409A1/en not_active Abandoned
-
2024
- 2024-01-26 JP JP2024010504A patent/JP2024072291A/ja not_active Ceased
- 2024-12-17 AU AU2024278490A patent/AU2024278490A1/en active Pending
-
2025
- 2025-01-16 US US19/024,203 patent/US20250381188A1/en active Pending
- 2025-03-27 JP JP2025054634A patent/JP2025118595A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8476284B2 (en) * | 2006-09-22 | 2013-07-02 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| WO2015061751A1 (en) * | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Methods of treating and preventing graft versus host disease |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022203810B2 (en) | Methods of treating and preventing alloantibody driven chronic graft versus host disease | |
| AU2022202686B2 (en) | Methods of treating and preventing graft versus host disease | |
| HK40086449A (en) | Methods of treating and preventing graft versus host disease | |
| EA045869B1 (ru) | Способы лечения и предотвращения болезни "трансплантат против хозяина" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |